Address Nirmatrelvir/Ritonavir (Paxlovid) Interactions
July 2022
You can help answer questions when patients with COVID-19 taking nirmatrelvir/ritonavir (Paxlovid) present to the hospital.
It’s too soon to say if patients taking nirmatrelvir/ritonavir should continue it on admission. It’s okay to complete the course...but you’ll likely need to use a patient’s home supply.
Be ready to manage interactions...since the ritonavir component is a strong CYP3A4 and P-glycoprotein inhibitor.Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote